Maravai LifeSciences Holdings, Inc. (MRVI)
- Previous Close
7.72 - Open
7.76 - Bid 7.25 x 200
- Ask 7.70 x 400
- Day's Range
7.60 - 7.95 - 52 Week Range
4.52 - 16.62 - Volume
1,274,690 - Avg. Volume
2,816,985 - Market Cap (intraday)
1.928B - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.90 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.88
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
www.maravai.comRecent News: MRVI
Performance Overview: MRVI
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRVI
Valuation Measures
Market Cap
1.01B
Enterprise Value
1.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.50
Price/Book (mrq)
2.43
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
1.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.19%
Return on Assets (ttm)
-0.81%
Return on Equity (ttm)
-16.33%
Revenue (ttm)
288.94M
Net Income Avi to Common (ttm)
-119.03M
Diluted EPS (ttm)
-0.90
Balance Sheet and Cash Flow
Total Cash (mrq)
574.96M
Total Debt/Equity (mrq)
77.35%
Levered Free Cash Flow (ttm)
43.83M